Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients

doi:10.4254/wjh.v16.i10.1158

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (217)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

HTML

110

Figures (1-3)

Sum=139

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=47

Oct 27, 2024 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Oct 27, 2024; 16(10): 1158-1168
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1158

Open in New Tab Full Size Figure Download Figure

Figure 1 The treatment methods for liver cancer are constantly advancing, evolving from surgery to systematic treatment[85-88]. HCC: Hepatocellular carcinoma; TACE: Transartical chemoembolization.

Open in New Tab Full Size Figure Download Figure

Figure 2 Mechanisms of programmed cell death 1/programmed cell death ligand 1 axis in hepatocellular carcinoma. HCC: Hepatocellular carcinoma; TCR: T cell receptor; PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand 1; MDSC: Myeloid derived suppressive cell.

Open in New Tab Full Size Figure Download Figure

Figure 3 Immunotherapy-based combination therapy for liver cancer. TACE: Transartical chemoembolization.

Citation: Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168
URL: https://www.wjgnet.com/1948-5182/full/v16/i10/1158.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i10.1158